Dr. Tse-Wen Chang, Chairman
Please see Founder
Dr. Hsing-Mao Art Chu, CEO
Dr. Chu earned his bachelor’s degree from Chang Gung University, followed by a master’s degree from National Yang Ming University and a Ph.D. from National Taiwan University. He conducted postdoctoral research at the Institute of Biological Chemistry, Academia Sinica, and in 2011 joined the laboratory of Distinguished Research Fellow Dr. Tse-Wen Chang at the Genomics Research Center, focusing on antibody engineering. His research centered on elucidating the molecular mechanisms underlying the interactions between CεmX and anti-CεmX.
In 2015, Dr. Chu joined Immunwork to lead R&D efforts using the proprietary T-E technology platform, advancing multiple drug programs. He has overseen six proof-of-concept successes, with two candidates entering human clinical trials, and is a co-inventor of more than 90 related patents. In 2023, Dr. Chu was appointed CEO of T-E Meds, while concurrently serving as Vice President of R&D at Immunwork. He currently serves as CEO of T-E Pharma, continuing to lead the company’s R&D and innovation efforts and driving novel drug candidates toward clinical development and commercialization.
Ms. Ying-Rong Lai, COO
Ms. Lai holds a Master’s degree in Biotechnology Management from National Taiwan University. Throughout her career, she has gained experience across multiple industries, including internal cost control and estimation, participation in industry tenders, and business management. She also spent several years in the higher education sector and engaged in both domestic and international trade, before ultimately entering the financial and accounting sector. She has demonstrated outstanding management experience across various business domains. With over a decade of experience in the financial industry, she has received multiple performance awards during her career.
In 2014, she was invited by Dr. Tse-Wen Chang to join the company’s executive team, assisting in the establishment of Immunwork and overseeing administrative and financial planning. She currently serves as Chief Operating Officer (COO) of T-E Pharma, responsible for company operations and overall management.
Dr. Chi-Jiun Peng, Director, Process Development and CMC
Dr. Peng completed his M.S. training in Radiochemistry at Yang-Ming University and obtained his Ph.D. in Chemistry from National Taiwan University. He possesses interdisciplinary expertise in radiopharmaceuticals, chemical biology, and the development of ARC and ADC. Dr. Peng previously served at Tri-Service General Hospital, where he was responsible for new drug development, clinical drug production, and clinical trial operations. He also led the positron emission tomography (PET) facility in successfully passing two cGMP inspections by the TFDA, establishing a quality management system that meets international standards. He has accumulated over ten years of practical experience in drug development, as well as GMP, CMC, and regulatory affairs.
Dr. Peng joined Immunwork in 2019, where he oversaw technology transfer and CDMO collaborations, successfully advancing two peptide drug candidates through Phase I clinical trials. In 2023, he joined T-E Meds and currently serves as Director of Process Development and CMC, leading CMC development strategies and serving as a key leader in formulation design and process development.
Dr. Allen Yueh-Hsiang Yu, Director, Preclinical Development and Drug Regulatory
Dr. Yu received a Ph.D. from the Graduate Institute of Life Sciences jointly established by National Defense Medical Center, National Health Research Institutes, and Academia Sinica. During his postdoctoral training, he worked at the Genomics Research Center of Academia Sinica, where he was responsible for establishing a single B-cell antibody cloning platform and identifying therapeutic antibodies targeting various infectious diseases.
In 2019, Dr. Yu joined Immunwork, where he has been primarily responsible for preclinical development activities, including pharmacology, efficacy, pharmacokinetics, and safety evaluation of the long-acting peptide drug TE-8214 and the antibody-drug conjugates (ADCs) TE-1146 and TE-1182. He successfully advanced TE-8214 into clinical trials. More recently, he completed discussions with the U.S. FDA regarding the TE-1146 project and introduced New Approach Methodologies (NAMs) for safety evaluation, aligning with the latest international development trends to enhance clinical trial safety and precision, while actively advancing the project toward clinical studies. He currently serves as Director of Preclinical Development and Drug Regulatory at T-E Meds, where he continues to lead the preclinical research team in advancing multiple drug candidates into clinical development.
Dr. Cédric Grauffel, Manager, T-E Drug Design
Dr. Cédric received his Ph.D. in Chemistry at the University of Strasbourg, France in 2009 and did postdoctoral research on peripheral membrane proteins and protease inhibitors in the University of Bergen, Norway in 2010-13. He came to the Institute of Biomedical Sciences, Academia Sinica in 2013, where he worked on metal competition in proteins and aspects of drug design.
In 2022, Dr. Cédric joined Immunwork, applying his expertise in theoretical computational chemistry and molecular simulation to drug design and development . In 2023, he transitioned to T-E Meds where he works on improving linker technology for constructing next-generation T-E pharmaceuticals. There, he actively participated in designing a new ADC product with an improved linker. Currently, his professional activities also involve intellectual property and market due diligence, which he achieves by establishing and managing internal databases and systematically conducting freedom-to-operate (FTO) evaluations.
Dr. Tzu-Chen Lin, Project Leader, ADC
Dr. Lin received her Ph.D. in Chemistry and Chemical Biology from the Technical University of Dortmund, Germany, and the International Max Planck Research School for Living Matter (IMPRS-LM, former IMPRS-CMB) in 2022. She continued her post-doctoral research at the Technical University of Dortmund in 2022-2024. During her Ph.D. studies, she focused on using chemical biology tools to modulate and investigate the functions of key epigenetic regulators. In her post-doctoral research, she led a team in developing high-throughput screening methods to identify small molecule inhibitors for an important epigenetic regulator protein.
After joining T-E Meds in 2024, Dr. Lin has been working on new drug bundle design and ADC technology platform optimization. She is currently leading the project for T-E Meds’ dual-payload ADC and is actively driving the process development.
R&D Organization
The R&D department is currently organized into four core teams:
- Drug Bundle Design: Led by Dr. Cédric Grauffel and Dr. Tzu-Chen Lin, focusing on innovative drug structure design;
- CMC: Overseen by Dr. Chi-Jiun Peng, responsible for process development and quality management;
- Pharmacology & Preclinical Development: Coordinated by Dr. Allen Yueh-Hsiang Yu, responsible for efficacy and safety evaluation;
- Clinical Development: Led by a senior clinical manager, responsible for trial design and execution.
This integrated structure enables T-E Meds to advance its pipeline and translate scientific innovation into clinical and commercial opportunities.